Literature DB >> 28654861

Aging alters mRNA expression of amyloid transporter genes at the blood-brain barrier.

Doreen Osgood1, Miles C Miller1, Arthur A Messier1, Liliana Gonzalez2, Gerald D Silverberg3.   

Abstract

Decreased clearance of potentially toxic metabolites, due to aging changes, likely plays a significant role in the accumulation of amyloid-beta (Aβ) peptides and other macromolecules in the brain of the elderly and in the patients with Alzheimer's disease (AD). Aging is the single most important risk factor for AD development. Aβ transport receptor proteins expressed at the blood-brain barrier are significantly altered with age: the efflux transporters lipoprotein receptor-related protein 1 and P-glycoprotein are reduced, whereas the influx transporter receptor for advanced glycation end products is increased. These receptors play an important role in maintaining brain biochemical homeostasis. We now report that, in a rat model of aging, gene transcription is altered in aging, as measured by Aβ receptor gene messenger RNA (mRNA) at 3, 6, 9, 12, 15, 20, 30, and 36 months. Gene mRNA expression from isolated cerebral microvessels was measured by quantitative polymerase chain reaction. Lipoprotein receptor-related protein 1 and P-glycoprotein mRNA were significantly reduced in aging, and receptor for advanced glycation end products was increased, in parallel with the changes seen in receptor protein expression. Transcriptional changes appear to play a role in aging alterations in blood-brain barrier receptor expression and Aβ accumulation.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; Alzheimer's disease; Amyloid transport genes: LRP-1, P-gp, and RAGE mRNA; Blood-brain barrier

Mesh:

Substances:

Year:  2017        PMID: 28654861      PMCID: PMC5728118          DOI: 10.1016/j.neurobiolaging.2017.05.011

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  78 in total

1.  Genetic and functional characteristics of the human in vivo LRP1/A2MR receptor suggested as a risk marker for Alzheimer's disease and other complex (degenerative) diseases.

Authors:  Christiane Gläser; Susanne Schulz; Katrin Handschug; Klaus Huse; Gerd Birkenmeier
Journal:  Neurosci Res       Date:  2004-09       Impact factor: 3.304

Review 2.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

3.  What lessons can be learned from failed Alzheimer's disease trials?

Authors:  Jeremy Toyn
Journal:  Expert Rev Clin Pharmacol       Date:  2015-04-10       Impact factor: 5.045

4.  Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.

Authors:  Yvonne Bouter; Jose Socrates Lopez Noguerola; Petra Tucholla; Gabriela A N Crespi; Michael W Parker; Jens Wiltfang; Luke A Miles; Thomas A Bayer
Journal:  Acta Neuropathol       Date:  2015-11       Impact factor: 17.088

5.  1α,25-Dihydroxyvitamin D3-liganded vitamin D receptor increases expression and transport activity of P-glycoprotein in isolated rat brain capillaries and human and rat brain microvessel endothelial cells.

Authors:  Matthew R Durk; Gary N Y Chan; Christopher R Campos; John C Peart; Edwin C Y Chow; Eason Lee; Ronald E Cannon; Reina Bendayan; David S Miller; K Sandy Pang
Journal:  J Neurochem       Date:  2012-11-01       Impact factor: 5.372

6.  Changes in gene expression profile in two multidrug resistant cell lines derived from a same drug sensitive cell line.

Authors:  Miguel Angelo Martins Moreira; Carolina Bagni; Marcos Barcelos de Pinho; Thaís Messias Mac-Cormick; Mateus dos Santos Mota; Flávio Eduardo Pinto-Silva; Nathalia Daflon-Yunes; Vivian Mary Rumjanek
Journal:  Leuk Res       Date:  2014-06-12       Impact factor: 3.156

7.  Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease.

Authors:  P V Arriagada; K Marzloff; B T Hyman
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

8.  Effects of ginkgo biloba extract EGb761 on expression of RAGE and LRP-1 in cerebral microvascular endothelial cells under chronic hypoxia and hypoglycemia.

Authors:  Fu-Ling Yan; Ying Zheng; Feng-Di Zhao
Journal:  Acta Neuropathol       Date:  2008-10-01       Impact factor: 17.088

9.  Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease.

Authors:  Miles C Miller; Rosemarie Tavares; Conrad E Johanson; Virginia Hovanesian; John E Donahue; Liliana Gonzalez; Gerald D Silverberg; Edward G Stopa
Journal:  Brain Res       Date:  2008-07-14       Impact factor: 3.252

10.  Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions.

Authors:  Jasmina B Mackic; James Bading; Jorge Ghiso; Larry Walker; Thomas Wisniewski; Blas Frangione; Berislav V Zlokovic
Journal:  Vascul Pharmacol       Date:  2002-06       Impact factor: 5.773

View more
  17 in total

1.  Altered clearance of beta-amyloid from the cerebrospinal fluid following subchronic lead exposure in rats: Roles of RAGE and LRP1 in the choroid plexus.

Authors:  Xiaoli Shen; Li Xia; Luqing Liu; Hong Jiang; Jonathan Shannahan; Yansheng Du; Wei Zheng
Journal:  J Trace Elem Med Biol       Date:  2020-04-08       Impact factor: 3.849

Review 2.  The blood brain barrier: Insights from development and ageing.

Authors:  Conor Delaney; Matthew Campbell
Journal:  Tissue Barriers       Date:  2017-09-28

Review 3.  Endothelial LRP1 - A Potential Target for the Treatment of Alzheimer's Disease : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.

Authors:  Steffen E Storck; Claus U Pietrzik
Journal:  Pharm Res       Date:  2017-09-25       Impact factor: 4.200

4.  Sodium tanshinone IIA sulfonate improves cognitive impairment via regulating Aβ transportation in AD transgenic mouse model.

Authors:  Hui-Han Ma; Can Wan; Lu-Di Zhang; Rong-Rong Zhang; Dong Peng; Li-Jun Qiao; Shi-Jie Zhang; Ye-Feng Cai; Hong-Qiang Huang
Journal:  Metab Brain Dis       Date:  2022-01-26       Impact factor: 3.584

5.  Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET.

Authors:  Viktoria Zoufal; Thomas Wanek; Markus Krohn; Severin Mairinger; Thomas Filip; Michael Sauberer; Johann Stanek; Thomas Pekar; Martin Bauer; Jens Pahnke; Oliver Langer
Journal:  J Cereb Blood Flow Metab       Date:  2018-10-24       Impact factor: 6.200

Review 6.  Treating viruses in the brain: Perspectives from NeuroAIDS.

Authors:  Melanie R Nicol; MaryPeace McRae
Journal:  Neurosci Lett       Date:  2021-01-30       Impact factor: 3.046

7.  The Blood-Brain Barrier in Alzheimer's Disease.

Authors:  Steffen E Storck; Anika M S Hartz; Claus U Pietrzik
Journal:  Handb Exp Pharmacol       Date:  2022

Review 8.  Inflammation: the link between comorbidities, genetics, and Alzheimer's disease.

Authors:  Estella A Newcombe; Judith Camats-Perna; Mallone L Silva; Nicholas Valmas; Tee Jong Huat; Rodrigo Medeiros
Journal:  J Neuroinflammation       Date:  2018-09-24       Impact factor: 8.322

9.  Blood-brain barrier: mechanisms governing permeability and interaction with peripherally acting μ-opioid receptor antagonists.

Authors:  Eugene R Viscusi; Andrew R Viscusi
Journal:  Reg Anesth Pain Med       Date:  2020-07-28       Impact factor: 6.288

10.  Age-Related Functional and Expressional Changes in Efflux Pathways at the Blood-Brain Barrier.

Authors:  Franciska Erdő; Péter Krajcsi
Journal:  Front Aging Neurosci       Date:  2019-07-30       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.